Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers

Journal of Clinical Pharmacy and Therapeutics

Volumn 32, Issue 2, 2007, Pages 161-167

  Mahatthanatrakul, W ^a   Nontaput, T ^a   Ridtitid, W ^a   Wongnawa, M ^a   Sunbhanich, M ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

CYP3A inducer; Drug drug interactions; Pharmacokinetics; Rifampin; Risperidone

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A; RIFAMPICIN; RISPERIDONE;

ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN; NOSE CONGESTION; OPEN STUDY; PHYSICAL EXAMINATION; PLASMA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; THAILAND; ULTRAVIOLET RADIATION; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DIZZINESS; DRUG INTERACTIONS; HALF-LIFE; HEADACHE; HUMANS; MALE; NASAL OBSTRUCTION; RIFAMPIN; RISPERIDONE; SPECTROPHOTOMETRY, ULTRAVIOLET; TABLETS; TIME FACTORS;

EID: 33947374728     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2007.00811.x     Document Type: Article

References (32)

1. Cutler NR (2001) Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. Journal of Clinical Psychiatry, 62(Suppl. 5), 10-13.
2. Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizopharenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychiatry, 58, 538-546.
3. Chouinard G, Amott W (1993) Clinical review of risperidone. Canadian Journal of Psychiatry, 38(Suppl. 3), S89-S95.
4. Heykants J, Huang ML, Mannens G et al. (1994) The pharmacokinetics of risperidone in humans: a summary. Journal of Clinical Psychiatry, 55(Suppl.), 13-17.
5. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J (1993) Absorption, metabolism, and excretion of risperidone in humans. Drug Metabolism and Disposition, 21, 1134-1141.
6. Huang ML, Van Peer A, Woestenborghs R et al. (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clinical Pharmacology and Therapeutics, 54, 257-268.
7. Fang J, Bourin M, Baker GB (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochrome P450 2D6 and 3A4. Naunyn Schmiederbergs Archive of Pharmacology, 359, 147-151.
8. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
9. Mula M, Monaco F (2002) Carbamazepine-risperidone interaction in patients with epilepsy. Clinical Neuropharmacology, 25, 97-100.
10. Spina E, Avenoso A, Facciola G et al. (2000) Plasma concentrations of risperidone and 9-hydroxyrisperidone. Effect of comedication with carbamazepine or valproate. Therapeutic Drug Monitoring, 22, 481-485.
11. Lane HY, Chang WH (1998) Risperidone-carbamazepine interactions: is cytochrome P450 3A involved? Journal of Clinical Psychiatry, 59, 430-431.
12. DeVane CL, Nemroff CB (2001) An evaluation of risperidone drug interactions. Journal of Clinical Psychopharmacology, 21, 408-416.
13. Jover F, Cuadrado JM, Andreu L, Merino J (2002) Reversible coma caused by risperidone-ritonavir interaction. Clinical Neuropharmacology, 25, 251-253.
14. Kelly DV, Beique LC, Bowmer MI (2002) Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Annals of Pharmacotherapy, 36, 827-830.
15. Jung SM, Kim KA, Cho HK, Jung IG, Park PW, Byun WT, Park JY (2005) Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clinical Pharmacology and Therapeutics, 78, 520-528.
16. Pea F, Furlanut M (2001) Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clinical Pharmacokinetics, 40, 833-868.
17. Vekatesan K (1992) Pharmacokinetic drug interactions with rifampin. Clinical Pharmacokinetics, 22, 47-65.
18. Avenoso A, Facciola G, Salemi M, Spina E (2000) Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reverse-phase liquid chromatography with ultraviolet detection. Journal of Chromatography B, 746, 173-181.
19. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
20. Villikka K, Kivisto KT, Backman JT, Olkkola KT, Neuvonen PJ (1996) Triazolam is ineffective in patients taking rifampin. Clinical Pharmacology and Therapeutics, 61, 8-14.
21. Zhou ZL, Li X, Peng HY et al. (2006) Multiple dose pharmacokinetics of risperidone and 9-hydroxyris-peridone in Chinese female patients with schizophrenia. Acta Pharmacologica Sinica, 27, 381-386.
22. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, WatkinsPB(1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. Journal of Clinical Investigation, 90, 1871-1878.
23. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Chaiyapol P, Sunbhanich M (2000) Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. Journal of Pharmacy and Pharmacology, 52, 1265-1269.
24. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M (2002) Rifampin markedly decreased plasma concentrations of praziquantel in healthy volunteers. Clinical Pharmacology and Therapeutics, 72, 505-513.
25. Villikka K, Kivisto KT, Neuvonen PJ (1999) The effect of rifampin on the oral and intravenous ondansetron. Clinical Pharmacology and Therapeutics, 65, 377-381.
26. Bork JA, Rogers T, Wedlund PJ, de Leon J (1999) A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. Journal of Clinical Psychiatry, 60, 469-476.
27. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Raungsri N, Sunbhanich M (2005) Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. Journal of Clinical Pharmacy and Therapeutics, 30, 285-290.
28. Scordo MG, Spina E, Facciola G, Avenoso A, Johansson I, Dahl ML (1999) Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl), 147, 300-305.
29. Mihara K, Kondo T, Yasui-Furukori N et al. (2003) Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in japanese patients with schizophrenia. Therapeutic Drug Monitoring, 25, 287-293.
30. Ono S, Mihara K, Suzuki A et al. (2002) Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (Berl), 162, 50-54.
31. Riedel M, Schwarz MJ, Strassnig M et al. (2005) Risperidone plasma levels, clinical response and side-effects. European Archive of Psychiatry and Clinical Neurosicence, 255, 261-268.
32. Hiemke C, Dragicevic A, Grunder G et al. (2004) Therapeutic monitoring of new antipsychotic drugs. Therapeutic Drug Monitoring, 26, 156-160.